<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1437">
  <stage>Registered</stage>
  <submitdate>29/06/2006</submitdate>
  <approvaldate>7/07/2006</approvaldate>
  <actrnumber>ACTRN12606000286549</actrnumber>
  <trial_identification>
    <studytitle>Lycopene supplementation in stable asthma</studytitle>
    <scientifictitle>A placebo-controlled, double-blind, randomised control trial using lycopene-rich supplements to reduce neutrophlic airway inflammation in asthma</scientifictitle>
    <utrn />
    <trialacronym>DAX</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Following a 2 week washout on a low antioxidant diet, subjects receive oral lycopene supplements (45mg/day) for 12 weeks. A comparison group consume a diet high in antioxidants for the duration of the study.</interventions>
    <comparator>Placebo for 12 weeks, A comparison group consume a diet high in antioxidants for the duration of the study.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Induced sputum neutrophil count</outcome>
      <timepoint>Measured at baseline, week 2,6,10 and 14.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma Control Score</outcome>
      <timepoint>Measured at baseline, week 2,6,10 and 14.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Airway hyperresponsiveness </outcome>
      <timepoint>Measured at baseline, week 2,6,10 and 14.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable asthma, Non-smokers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Other respiratory disease, Vitamin or mineral use.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed by blinded list held by independent statistician</concealment>
    <sequence>Computer generated sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>10/07/2006</anticipatedstartdate>
    <actualstartdate>11/07/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/02/2009</actualenddate>
    <samplesize>192</samplesize>
    <actualsamplesize>139</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Hunter New England Health Service</primarysponsorname>
    <primarysponsoraddress>Lookout Rd, New Lambton NSW 2305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study in asthma examines the ability of lycopene-rich supplements to improve neutrophilic inflammation and disease control, and to reduce exacerbation frequency and severity. It uses a blinded comparison of subjects consuming lycopene-rich supplements versus placebo. It also includes a comparison group of subjects with a high dietary intake of antioxidants.</summary>
    <trialwebsite />
    <publication>Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J. 2011 Sep;38(3):594-602. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>John Hunter Hospital (Hunter New England Health Service)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/06/2006</ethicapprovaldate>
      <hrec>05/03/09/3.09</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+61 2 4042 0147</phone>
      <fax>+61 2 4042 0046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+61240420147</phone>
      <fax>+61 2 40420046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bronwyn Berthon</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+ 61 2 40420116</phone>
      <fax>+61 2 40420046</fax>
      <email>bronwyn.berthon@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+61240420147</phone>
      <fax />
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>